For the quarter ended June 2024, Staar Surgical (STAA) reported revenue of $99.01 million, up 7.3% over the same period last year. EPS came in at $0.33, compared to $0.40 in the year-ago quarter. The reported revenue represents a surprise of +4.05% over the Zacks Consensus Estimate of $95.15 million. With the consensus EPS estimate being $0.25, the EPS surprise was +32.00%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Staar Surgical (STAA) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this maker of implantable lenses would post earnings of $0.05 per share when it actually produced earnings of $0.06, delivering a surprise of 20%. Over the last four quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 28, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) Delaware 95-3797439 (State or Other Jurisdiction of Incorporation or Organizati ...

Exhibit 99.1 STAAR Surgical Reports Second Quarter 2024 Results Record Quarterly Net Sales of $99.0 Million; $100.4 Million in Constant Currency Raises Fiscal 2024 Net Sales and Adjusted EBITDA Outlook LAKE FOREST, CA, August 7, 2024 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the second quarter ended June 28, 2024. Second Qua ...

STAAR Surgical Company (NASDAQ:STAA) Q1 2024 Results Conference Call May 7, 2024 4:15 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - President, CEO Patrick Williams - CFO Conference Call Participants Margaret Kaczor - William Blair Tom Stephan - Stifel Patrick Wood - Morgan Stanley Young Li - Jefferies John Young - Canaccord Anthony Petrone - Mizuho George Sellers - Stephens Operator Greetings. Welcome to the STAAR Surgical First Quarter 2024 Earnings Call and Webcast. [Operator Instructions] ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 29, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) Delaware 95-3797439 (State or Other Jurisdiction of (I.R.S. Employer Incorpora ...

Exhibit 99.1 STAAR Surgical Reports First Quarter 2024 Results EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA LAKE FOREST, CA, May 7, 2024 --- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact name of registrant as specified in its charter) Delaware 95-3797439 (State or other jurisdiction o ...

STAAR Surgical Company (NASDAQ:STAA) Q4 2023 Earnings Conference Call February 26, 2024 4:15 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Patrick Wood - Morgan Stanley John Young - Canaccord Margaret Andrew - William Blair George Sellers - Stephens Inc. Ryan Zimmerman - BTIG Anthony Petrone - Mizuho Group Matthew O'Brien - Piper Sandl ...

Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 29, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 UNITED STATES SECURITIES AND EXCHANGE COMMISSION STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlan ...